Allianz Asset Management GmbH Trims Position in DexCom, Inc. (DXCM)

Allianz Asset Management GmbH trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 776,100 shares of the medical device company’s stock after selling 48,251 shares during the period. Allianz Asset Management GmbH owned about 0.89% of DexCom worth $37,971,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DXCM. Advisor Group Inc. boosted its holdings in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. IFP Advisors Inc boosted its holdings in DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares in the last quarter. Toronto Dominion Bank boosted its holdings in DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after purchasing an additional 354 shares during the period.

In other DexCom news, Director Mark G. Foletta sold 2,500 shares of the stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $54.95, for a total value of $137,375.00. Following the completion of the sale, the director now owns 4,952 shares in the company, valued at approximately $272,112.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew K. Balo sold 6,490 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,954 shares of company stock valued at $2,266,296. Insiders own 1.70% of the company’s stock.

Shares of DexCom, Inc. (NASDAQ DXCM) opened at $59.97 on Friday. DexCom, Inc. has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

A number of equities analysts recently commented on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 price objective (down previously from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (down previously from $85.00) on shares of DexCom in a research note on Thursday, September 28th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Northland Securities lowered shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $85.00 to $60.00 in a research note on Thursday, September 28th. Finally, J P Morgan Chase & Co lowered shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $93.00 to $71.00 in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and an average target price of $70.69.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/08/allianz-asset-management-gmbh-trims-position-in-dexcom-inc-dxcm.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply